Benjamin F. Edwards & Company, Inc. Incyte Corp Transaction History

Benjamin F. Edwards & Company, Inc.

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 06, 2024	BUY	$52.16 - $64.19 $365 - $449	7 New	7 $0
Q4 2021 Feb 07, 2022	SELL	$63.34 - $74.11 $68,850 - $80,557	-1,087 Closed	0 $0
Q3 2021 Nov 02, 2021	BUY	$68.67 - $84.02 $17,991 - $22,013	262 Added 31.76%	1,087 $75,000
Q2 2021 Aug 11, 2021	BUY	$79.87 - $87.53 $16,373 - $17,943	205 Added 33.06%	825 $69,000
Q1 2021 May 14, 2021	BUY	$76.02 - $100.5 $18,016 - $23,818	237 Added 61.88%	620 $50,000
Q4 2020 Feb 16, 2021	BUY	$80.74 - $97.7 $10,253 - $12,407	127 Added 49.61%	383 $33,000
Q3 2020 Nov 13, 2020	SELL	$85.07 - $109.69 $1,361 - $1,755	-16 Reduced 5.88%	256 $23,000
Q2 2020 Aug 14, 2020	SELL	$74.18 - $108.93 $5,192 - $7,625	-70 Reduced 20.47%	272 $28,000
Q1 2020 May 07, 2020	SELL	$63.18 - $85.97 $14,720 - $20,031	-233 Reduced 40.52%	342 $25,000
Q4 2019 Feb 06, 2020	BUY	$73.04 - $95.72 $9,495 - $12,443	130 Added 29.21%	575 $50,000
Q3 2019 Nov 05, 2019	BUY	$72.82 - $86.52 $27,890 - $33,137	383 Added 617.74%	445 $33,000
Q1 2019 May 15, 2019	BUY	$63.56 - $88.17 $3,940 - $5,466	62 New	62 $5,000

644

186M

714K

557K

Ticker INCY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 222,431,008
Market Cap $16B
Description
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as ...

Get notified when there are updates to the investment portfolio of Benjamin F. Edwards & Company, Inc., based on Form 13F filings with the SEC.

Stay updated on Benjamin F. Edwards & Company, Inc. with notifications on news.